Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Psychiatr Res ; 173: 25-33, 2024 May.
Article in English | MEDLINE | ID: mdl-38479345

ABSTRACT

Increased levels of inflammation markers have been found in the peripheral tissue of individuals with bipolar disorder (BD), especially during mood episodes. Previous studies found distinctive inflammatory profiles across different brain regions, but potential associations with clinical symptoms are still lacking. This study aims to evaluate the association of neuropsychiatric symptoms with inflammatory markers in the hippocampus and cingulate of individuals with BD. Levels of IL-1ß, IL-6, IL-17A, cortisol, and C-reactive protein (CRP) were measured in the hippocampus and anterior cingulate of 14 BD individuals and their non-psychiatric controls. Neuropsychiatric symptoms present in the three months before death were assessed using the Neuropsychiatric Inventory (NPI). In the BD group, greater NPI scores were associated with higher IL-6 in the hippocampus (p = 0.011) and cingulate (p = 0.038) and higher IL-1ß (p = 0.039) in the hippocampus. After adjusting for age, sex and CDR, IL-1ß and IL-6 were still associated with higher NPI in the hippocampus. In correlation analysis considering both BD and their controls, moderate positive associations were found between NPI and IL-6 and cortisol in the hippocampus (p < 0.001 and p = 0.006) and cingulate (p = 0.024 and p = 0.016), IL-1ß (p < 0.001) and IL-17A in the hippocampus (p = 0.002). No difference in inflammatory markers was found according to type of psychotropic medication used. Hence, in individuals with BD, neuropsychiatric symptoms were differently associated with specific inflammatory cytokines and CRP in the hippocampus and cingulate. These results suggest that the neuroinflammatory changes occurring in BD may be more complex than previously expected and could be associated with clinical manifestations.


Subject(s)
Bipolar Disorder , Humans , Bipolar Disorder/drug therapy , Gyrus Cinguli/diagnostic imaging , Gyrus Cinguli/metabolism , Interleukin-17/metabolism , Interleukin-17/therapeutic use , Interleukin-6/metabolism , Hydrocortisone , Hippocampus/diagnostic imaging , Hippocampus/metabolism , C-Reactive Protein/metabolism
2.
Neurobiol Aging ; 117: 107-116, 2022 09.
Article in English | MEDLINE | ID: mdl-35709536

ABSTRACT

Associations between age-related neuropathological lesions and adult-onset lifetime major depressive disorder (a-MDD), late-life MDD (LLD), or depressive symptoms close to death (DS) were examined in a large community sample of non-demented older adults. Seven hundred forty-one individuals (age at death = 72.2 ± 11.7 years) from the Biobank for Aging Studies were analyzed. a-MDD was present in 54 (7.3%) participants, LLD in 80 (10.8%), and DS in 168 (22.7%). After adjustment for covariates and compared to controls, a-MDD, LDD and DS were associated with small vessel disease (p = 0.039, p = 0.003, and p = 0.003 respectively); LLD, and DS were associated with brain infarcts (p = 0.012, p = 0.018, respectively) and Lewy body disease (p = 0.043, p = 0.002, respectively). DS was associated with beta-amyloid plaque burden (p = 0.027) and cerebral amyloid angiopathy (p = 0.035) in cognitively normal individuals (Clinical Dementia Rating scale = 0). Vascular brain pathology was the strongest correlate of clinical depictions of depression in the absence of dementia, corroborating the vascular hypothesis of depression. Lewy body pathology underlay DS. An older adult with DS or LLD should be monitored for possible cognitive decline or neurodegenerative disorders.


Subject(s)
Alzheimer Disease , Dementia , Depressive Disorder, Major , Lewy Body Disease , Aged , Alzheimer Disease/pathology , Brain/pathology , Dementia/pathology , Depression , Depressive Disorder, Major/pathology , Humans , Lewy Bodies/pathology , Lewy Body Disease/pathology , Plaque, Amyloid/pathology
3.
Neurobiol Aging ; 61: 1-12, 2018 01.
Article in English | MEDLINE | ID: mdl-29031088

ABSTRACT

Clarifying the mechanisms connecting neurofibrillary tangle (NFT) neurotoxicity to neuronal dysfunction in humans is likely to be pivotal for developing effective treatments for Alzheimer's disease (AD). To model the temporal progression of AD in humans, we used a collection of brains with controls and individuals from each Braak stage to quantitatively investigate the correlation between intraneuronal caspase activation or macroautophagy markers, NFT burden, and neuronal loss, in the dorsal raphe nucleus and locus coeruleus, the earliest vulnerable areas to NFT accumulation. We fit linear regressions with each count as outcomes, with Braak score and age as the predictors. In progressive Braak stages, intraneuronal active caspase-6 positivity increases both alone and overlapping with NFTs. Likewise, the proportion of NFT-bearing neurons showing autophagosomes increases. Overall, caspases may be involved in upstream cascades in AD and are associated with higher NFTs. Macroautophagy changes correlate with increasing NFT burden from early AD stages.


Subject(s)
Alzheimer Disease/etiology , Alzheimer Disease/pathology , Brain/pathology , Cell Death , Neurofibrillary Tangles/pathology , Neurons/pathology , Aged , Aged, 80 and over , Autophagosomes , Autophagy/physiology , Caspase 6/metabolism , Caspase 6/physiology , Disease Progression , Female , Humans , Male , Middle Aged
4.
Proteomics Clin Appl ; 9(9-10): 832-7, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26059592

ABSTRACT

Neurodegenerative diseases (NDs), such as Alzheimer's disease and Parkinson's disease, are among the most debilitating neurological disorders, and as life expectancy rises quickly around the world, the scientific and clinical challenges of dealing with them will also increase dramatically, putting increased pressure on the biomedical community to come up with innovative solutions for the understanding, diagnosis, and treatment of these conditions. Despite several decades of intensive research, there is still little that can be done to prevent, cure, or even slow down the progression of NDs in most patients. There is an urgent need to develop new lines of basic and applied research that can be quickly translated into clinical application. One way to do this is to apply the tools of proteomics to well-characterized samples of human brain tissue, but a closer partnership must still be forged between proteomic scientists, brain banks, and clinicians to explore the maximum potential of this approach. Here, we analyze the challenges and potential benefits of using human brain tissue for proteomics research toward NDs.


Subject(s)
Brain/metabolism , Neurodegenerative Diseases/metabolism , Neurodegenerative Diseases/pathology , Proteomics/methods , Humans
5.
J Neurol Sci ; 283(1-2): 2-8, 2009 Aug 15.
Article in English | MEDLINE | ID: mdl-19289241

ABSTRACT

The histopathological counterpart of white matter hyperintensities is a matter of debate. Methodological and ethical limitations have prevented this question to be elucidated. We want to introduce a protocol applying state-of-the-art methods in order to solve fundamental questions regarding the neuroimaging-neuropathological uncertainties comprising the most common white matter hyperintensities [WMHs] seen in aging. By this protocol, the correlation between signal features in in situ, post mortem MRI-derived methods, including DTI and MTR and quantitative and qualitative histopathology can be investigated. We are mainly interested in determining the precise neuroanatomical substrate of incipient WMHs. A major issue in this protocol is the exact co-registration of small lesion in a tridimensional coordinate system that compensates tissue deformations after histological processing. The protocol is based on four principles: post mortem MRI in situ performed in a short post mortem interval, minimal brain deformation during processing, thick serial histological sections and computer-assisted 3D reconstruction of the histological sections. This protocol will greatly facilitate a systematic study of the location, pathogenesis, clinical impact, prognosis and prevention of WMHs.


Subject(s)
Brain/pathology , Cerebrovascular Disorders/pathology , Nerve Fibers, Myelinated/pathology , Adult , Aged , Aging/pathology , Anisotropy , Diffusion Magnetic Resonance Imaging , Female , Humans , Imaging, Three-Dimensional , Immunohistochemistry , Magnetic Resonance Imaging , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...